Aclaris Therapeutics

Founder Neal Walker returned to the CEO role in February 2025 and chairs the board. His background is in dermatology and prior company building. As of the 2026 proxy, he beneficially owned about 3.18 million shares, or roughly 2.6 percent, which provides alignment but is not dominant control.

The team has moved decisively after the 2023 MK2 setback, but the track record still requires validation through successful controlled trials and smart partnering. Score reflects credible leadership and domain expertise, offset by past clinical disappointments and the need to prove the new strategy in 2026–2027.